One of the greatest disappointments in the war on cancer is that survival for patients with metastasis remains abysmal (much less than 25%), highlighting the dire need for improved treatment options. Metastasis is inexplicably complex, requires coordinated expression of multiple genes and proteins, and requires intricate communication of tumor cells to the constantly-changing environments as cells disseminate and colonize other tissues [1] . While the process is fortuitously ineffi cient, when cells succeed there are few eff ective treatment options. In addition to improving our clinical trial system [2], attention cannot be drawn away from the basic research that will unravel the cellular networks that drive metastasis.
recognized that metastatic cells interact with other cells, matrices and soluble molecules, roles of the microenviron ment are becoming increasingly appreciated. Among myriad signaling molecules contributing to metastatic behavior is transforming growth factor beta (TGF-β).
A long-time, unsolved mystery in cancer biology is the paradoxical eff ect of TGF-β, which suppresses growth and tumorigenicity when cells are normal or near normal but somehow becomes a promoter of invasion and metastasis as neoplasms progress [3] . Both cell-autonomous and noncell-autonomous mechanisms have previously been invoked. In a recent publication by Taylor and colleagues [4] , however, a new intermediary in the process has been uncovered. Th e results also highlight how microenvironment conditions, in this case matrix, are not inert bystanders in cellular behavior; and how the authors began the process of sorting through TGF-β-miRNA pathways that diff erentially mediate growth and invasive behaviors.
Launching from Weaver and colleagues' fi ndings showing that tumor cells respond to matrix stiff ness diff erentially [5] and that matrix rigidity -that often accompanies desmoplasia -diff erentially regulates TGF-β responses, the Schiemann group grew breast carcinoma cells in two diff erent matrices with a goal to mimic matrix tensegrity at primary tumors and metastatic sites [6] . Using threedimensional cultures of mammary carcinoma cells treated with TGF-β in stiff or fractile matrices (Cultrex ± type I collagen, respectively), diff erential responses were observed as expected. Global miRNA expression analyses were performed and a panel of metastasis-associated miRNA, so-called metastamir [7] , was identifi ed. Th ey smartly focused on one miRNA, miR-181a, that was regulated in both tissue culture conditions and in three isogenic murine mammary carcinoma cell lines. Th e remainder of their studies characterized the role of miR-181a in promoting mammary cancer progression. Inhibition of miR-181a clearly altered lung colonization after tail vein injection. However, tumor latency, growth and dissemination did not appear to change (Note: the inhibition was lost in the tumor cells that successfully colonized, suggesting that they were revertants.) Th ese
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Transforming growth factor beta (TGF-β) has received noteworthy attention in the recent past due to its unique characteristic of functionally switching roles from tumor suppressor to metastasis promoter. To uncover the black box surrounding the mechanisms of TGF-β, Taylor and colleagues performed global miRNA expression analyses using a murine mammary carcinoma progression model. They discovered multiple miRNA regulated by TGF-β and matrix stiff ness. Focusing on miR-181a, they uncovered an intricate pathway regulating breast cancer metastasis that sheds new insight into metastasis regulation that may prove useful in clinical settings.
fi ndings further highlight how metastasis is a distinct phenotype from primary tumor growth.
As various laboratories dissect molecular mechanisms of metastatic spread, the identifi cation of signaling pathways, including networks connecting matrices, signaling molecules and miRNA, is emerging. miRNA are increasingly recognized as key regulators of networks controlling normal cell functions and pathologies [8] . Progress has been slowed somewhat in defi ning miRNA since each miRNA can have as few as one or as many as hundreds of targets. Superimposing the intricate cellular interactions occurring throughout the metastatic process and the inter connectivity of miRNA in various signaling cascades, the complexity multiplies. Nonetheless, several themes begin to emerge.
We [9, 10] and others [11, 12] previously showed a metastasis suppressor-metastamir pathway; others have linked TGF-β signaling with miRNA that regulate epithelialmesenchymal transition [13] ; and, still others link miRNA as feedback to traditional signaling pathways [14] . As these networks become more fi nely elucidated, they are beginning to defi ne metastasis mechanisms and patterns for particular molecular subtypes of cancer. Invoking miRNA represents an exciting avenue for translational studies since miRNA have taken centerstage in recent years as both biomarkers and directed therapy against cancer [15] . Th e miR-181a expression inversely correlated with patient survival, serving as a promising biomarker or therapeutic target. However, we urge caution with imposing fi ndings on cancer subtypes at this time, since more extensively powered studies will be required to make fi rm such assertions.
While there is substantial promise, questions remain. How does matrix (composition or tensegrity) regulate TGF-β signaling? Do all of the miRNA changed by TGF-β work in concert? Are miRNA networks dependent upon the microenvironment? Are there bypass pathways or is there redundancy in miRNA pathways? How many of the other miRNA regulated by TGF-β also change growth or metastasis? Are there ways in which the microenvironment could be treated to induce the growth-suppressive TGF-β eff ects? Th ese (and many other) questions will not be addressed in a single study. But tackling the pathways systematically (that is, one molecule at a time) may uncover networks that will translate into relevant personalized treatments.
Abbreviations miRNA, micro RNA; TGF-β, transforming growth factor beta.
